Literature DB >> 3009792

Pharmacological evidence that human intralobar airways do not contain different receptors that mediate contractions to leukotriene C4 and leukotriene D4.

C K Buckner, R D Krell, R B Laravuso, D B Coursin, P R Bernstein, J A Will.   

Abstract

Contractile responses to leukotriene (LT)C4, LTD4 and LTE4 were examined in intralobar airways from human lung obtained after surgical resection. In addition, the ability of the LT receptor antagonist FPL55712 to antagonize responses to LTC4 and LTD4 was quantified (by calculating -log molar KB values) under experimental conditions designed to minimize metabolic transformation of the LTs. In the absence of drug pretreatment, the three peptide LTs were approximately equipotent and produced similar maximum degrees of contraction. L-Serine borate complex, 45 mM, used as an inhibitor of the degradation of LTC4 to LTD4 by the enzyme gamma-glutamyl transpeptidase, in paired airway segments (adjacent segments from the same branch), produced a small degree (about 3-fold) of shift to the right of the dose-response curve and reduction of the maximum response to LTC4. L-Cysteine, 3 mM, used as an inhibitor of the degradation of LTD4 to LTE4 by the enzyme aminopeptidase, in paired segments, did not alter the dose-response effects of LTD4 or appear to further alter the dose-response effects of LTC4 when applied together with L-serine borate complex in unpaired (nonadjacent) segments. The -log molar KB value for FPL55712 (about 6) was similar for antagonism of responses to both LTC4 and LTD4 in the absence or presence of treatment with the metabolic inhibitors L-serine borate complex, L-cysteine or a combination of the two treatments. The results suggest that inhibition of the enzymes involved in the pathway from LTC4 to LTE4 has little consequence in human airways because the three peptide LTs are approximately equipotent.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009792

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

Review 1.  Leukotriene receptors.

Authors:  S E Dahlén
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Leukotriene activity modulation in asthma.

Authors:  S L Spector
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

Review 3.  Anti-leukotrienes in asthma: yet to arrive.

Authors:  G Gupta
Journal:  Indian J Pediatr       Date:  2000-02       Impact factor: 1.967

4.  Pharmacological evidence for a novel cysteinyl-leukotriene receptor subtype in human pulmonary artery smooth muscle.

Authors:  Laurence Walch; Xavier Norel; Magnus Bäck; Jean-Pierre Gascard; Sven-Erik Dahlén; Charles Brink
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

5.  Antigen stimulation of human pulmonary smooth muscle: an in vitro model of inflammation.

Authors:  I Gorenne; C Labat; J P Gascard; C Brink
Journal:  Cell Biol Toxicol       Date:  1996-12       Impact factor: 6.691

Review 6.  Airway receptors.

Authors:  P J Barnes
Journal:  Postgrad Med J       Date:  1989-08       Impact factor: 2.401

7.  Antigen-induced contraction of guinea-pig isolated trachea: studies with novel inhibitors and antagonists of arachidonic acid metabolites.

Authors:  T R Jones; L Charette; D Denis
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

8.  Disruption of gamma-glutamyl leukotrienase results in disruption of leukotriene D(4) synthesis in vivo and attenuation of the acute inflammatory response.

Authors:  Z Z Shi; B Han; G M Habib; M M Matzuk; M W Lieberman
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

9.  L-648,051, a novel cysteinyl-leukotriene antagonist is active by the inhaled route in man.

Authors:  J M Evans; N C Barnes; J T Zakrzewski; D G Sciberras; E G Stahl; P J Piper; J F Costello
Journal:  Br J Clin Pharmacol       Date:  1989-08       Impact factor: 4.335

Review 10.  Using guinea pigs in studies relevant to asthma and COPD.

Authors:  Brendan J Canning; Yangling Chou
Journal:  Pulm Pharmacol Ther       Date:  2008-02-02       Impact factor: 3.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.